Therapeutic Concepts in Succinate Semialdehyde Dehydrogenase (SSADH; ALDH5a1) Deficiency (gamma-hydroxybutyric Aciduria). Hypotheses Evolved from 25 Years of Patient Evaluation, Studies in Aldh5a1-/- Mice and Characterization of Gamma-hydroxybutyric...

Overview

Journal J Inherit Metab Dis

Publisher Wiley

Date 2007 Apr 26

PMID 17457693

Citations 20

Authors

I Knerr

P L Pearl

T Bottiglieri

O Carter Snead

C Jakobs

K M Gibson

Affiliations

Soon will be listed here.

Abstract

We overview the pathophysiological bases, clinical approaches and potential therapeutic options for succinate semialdehyde dehydrogenase (SSADH; EC1.2.1.24) deficiency (gamma-hydroxybutyric aciduria, OMIM 271980, 610045) in relation to studies on SSADH gene-deleted mice, outcome data developed from 25 years of patient evaluation, and characterization of gamma-hydroxybutyric acid (GHB) pharmacology in different species. The clinical picture of this disorder encompasses a wide spectrum of neurological and psychiatric dysfunction, such as psychomotor retardation, delayed speech development, epileptic seizures and behavioural disturbances, emphasizing the multifactorial pathophysiology of SSADH deficiency. The murine SSADH-/- (e.g. Aldh5a1-/-) mouse model suffers from epileptic seizures and succumbs to early lethality. Aldh5a1-/- mice accumulate GHB and gamma-aminobutyric acid (GABA) in the central nervous system, exhibit alterations of amino acids such as glutamine (Gln), alanine (Ala) and arginine (Arg), and manifest disturbances in other systems including dopamine, neurosteroids and antioxidant status. Therapeutic concepts in patients with SSADH deficiency and preclinical therapeutic experiments are discussed in light of data collected from research in Aldh5a1-/- mice and animal studies of GHB pharmacology; these studies are the foundation for novel working approaches, including pharmacological and dietary trials, which are presented for future evaluation in this disease.

Citing Articles

Glioma Cells Expressing High Levels of ALDH5A1 Exhibit Enhanced Migration Transcriptional Signature in Patient Tumors.

Piperi C, Saurty-Seerunghen M, Levidou G, Sepsa A, Trigka E, Klonou A Neurotherapeutics. 2023; 20(3):881-895.

PMID: 36976494 PMC: 10275844. DOI: 10.1007/s13311-023-01354-8.

γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology.

Felmlee M, Morse B, Morris M AAPS J. 2021; 23(1):22.

PMID: 33417072 PMC: 8098080. DOI: 10.1208/s12248-020-00543-z.

Evidence of redox imbalance in a patient with succinic semialdehyde dehydrogenase deficiency.

Niemi A, Brown C, Moore T, Enns G, Cowan T Mol Genet Metab Rep. 2016; 1:129-132.

PMID: 27896081 PMC: 5121295. DOI: 10.1016/j.ymgmr.2014.02.005.

Adrenal cortex expression quantitative trait loci in a German Holstein × Charolais cross.

Brand B, Scheinhardt M, Friedrich J, Zimmer D, Reinsch N, Ponsuksili S BMC Genet. 2016; 17(1):135.

PMID: 27716033 PMC: 5053117. DOI: 10.1186/s12863-016-0442-x.

Correlation of blood biomarkers with age informs pathomechanisms in succinic semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism.

Jansen E, Vogel K, Salomons G, Pearl P, Roullet J, Gibson K J Inherit Metab Dis. 2016; 39(6):795-800.

PMID: 27686230 PMC: 5115636. DOI: 10.1007/s10545-016-9980-7.

References

Goodwin A, Griffiths R, Brown P, Froestl W, Jakobs C, Gibson K . Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons. Psychopharmacology (Berl). 2006; 189(1):71-82. DOI: 10.1007/s00213-006-0534-9. View

Dervent A, Gibson K, Pearl P, Salomons G, Jakobs C, Yalcinkaya C . Photosensitive absence epilepsy with myoclonias and heterozygosity for succinic semialdehyde dehydrogenase (SSADH) deficiency. Clin Neurophysiol. 2004; 115(6):1417-22. DOI: 10.1016/j.clinph.2004.01.002. View

Trabace L, Kendrick K . Nitric oxide can differentially modulate striatal neurotransmitter concentrations via soluble guanylate cyclase and peroxynitrite formation. J Neurochem. 2000; 75(4):1664-74. DOI: 10.1046/j.1471-4159.2000.0751664.x. View

Gupta M, Greven R, Jansen E, Jakobs C, Hogema B, Froestl W . Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (gamma-hydroxybutyric aciduria). J Pharmacol Exp Ther. 2002; 302(1):180-7. DOI: 10.1124/jpet.302.1.180. View

Struys E, Verhoeven N, Jansen E, Ten Brink H, Gupta M, Burlingame T . Metabolism of gamma-hydroxybutyrate to d-2-hydroxyglutarate in mammals: further evidence for d-2-hydroxyglutarate transhydrogenase. Metabolism. 2006; 55(3):353-8. DOI: 10.1016/j.metabol.2005.09.009. View

Gibson K, Christensen E, Jakobs C, Fowler B, Clarke M, Hammersen G . The clinical phenotype of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria): case reports of 23 new patients. Pediatrics. 1997; 99(4):567-74. DOI: 10.1542/peds.99.4.567. View

Guarneri P, Guarneri R, La Bella V, Piccoli F . Interaction between uridine and GABA-mediated inhibitory transmission: studies in vivo and in vitro. Epilepsia. 1985; 26(6):666-71. DOI: 10.1111/j.1528-1157.1985.tb05709.x. View

Brancucci A, Berretta N, Mercuri N, Francesconi W . Presynaptic modulation of spontaneous inhibitory postsynaptic currents by gamma-hydroxybutyrate in the substantia nigra pars compacta. Neuropsychopharmacology. 2003; 29(3):537-43. DOI: 10.1038/sj.npp.1300344. View

Antolin I, Mayo J, Sainz R, del Brio M, Herrera F, Martin V . Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res. 2002; 943(2):163-73. DOI: 10.1016/s0006-8993(02)02551-9. View

10.

Owens D, Boyce L, Davis M, Kriegstein A . Excitatory GABA responses in embryonic and neonatal cortical slices demonstrated by gramicidin perforated-patch recordings and calcium imaging. J Neurosci. 1996; 16(20):6414-23. PMC: 6578913. View

11.

Pearl P, Gibson K, Acosta M, Vezina L, Theodore W, Rogawski M . Clinical spectrum of succinic semialdehyde dehydrogenase deficiency. Neurology. 2003; 60(9):1413-7. DOI: 10.1212/01.wnl.0000059549.70717.80. View

12.

Shaw L, WESTERFELD W . A study of the enzymatic reactions involved in the formation of 5-hydroxy-4-ketohexanoic acid and its isomer, 5-keto-4-hydroxyhexanoic acid. Biochemistry. 1968; 7(4):1333-8. DOI: 10.1021/bi00844a013. View

13.

Visser J, Smith D, Moy S, Breese G, Friedmann T, Rothstein J . Oxidative stress and dopamine deficiency in a genetic mouse model of Lesch-Nyhan disease. Brain Res Dev Brain Res. 2002; 133(2):127-39. DOI: 10.1016/s0165-3806(02)00280-8. View

14.

Kimura T, Ho I, Yamamoto I . Uridine receptor: discovery and its involvement in sleep mechanism. Sleep. 2001; 24(3):251-60. DOI: 10.1093/sleep/24.3.251. View

15.

Kirmse K, Kirischuk S . Ambient GABA constrains the strength of GABAergic synapses at Cajal-Retzius cells in the developing visual cortex. J Neurosci. 2006; 26(16):4216-27. PMC: 6674013. DOI: 10.1523/JNEUROSCI.0589-06.2006. View

16.

Donarum E, Stephan D, Larkin K, Murphy E, Gupta M, Senephansiri H . Expression profiling reveals multiple myelin alterations in murine succinate semialdehyde dehydrogenase deficiency. J Inherit Metab Dis. 2006; 29(1):143-56. DOI: 10.1007/s10545-006-0247-6. View

17.

Owens D, Liu X, Kriegstein A . Changing properties of GABA(A) receptor-mediated signaling during early neocortical development. J Neurophysiol. 1999; 82(2):570-83. DOI: 10.1152/jn.1999.82.2.570. View

18.

Beaujean D, Vaudry D, Sieghart W, Luu-The V, Pelletier G, Vaudry H . gamma-Aminobutyric acid, acting through gamma -aminobutyric acid type A receptors, inhibits the biosynthesis of neurosteroids in the frog hypothalamus. Proc Natl Acad Sci U S A. 2000; 97(25):13925-30. PMC: 17677. DOI: 10.1073/pnas.240269897. View

19.

Louzada P, Paula Lima A, Mendonca-Silva D, Noel F, de Mello F, Ferreira S . Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders. FASEB J. 2004; 18(3):511-8. DOI: 10.1096/fj.03-0739com. View

20.

Gibson K, Sweetman L, Nyhan W, Jakobs C, Rating D, Siemes H . Succinic semialdehyde dehydrogenase deficiency: an inborn error of gamma-aminobutyric acid metabolism. Clin Chim Acta. 1983; 133(1):33-42. DOI: 10.1016/0009-8981(83)90018-9. View